Scientific Society of Kafr El-Sheikh DoctorsAfrican Journal of Gastroenterology and Hepatology2735-54892120190205The outcome of the sofosbuvir Based Therapy in the treatment of Hepatitis C Virus Genotype 4 in Egyptian patients118209236https://dx.doi.org/10.52378/alkj/2738ENWaleed Abdul FattahIsmailAssistant professor of internal medicine, gastroenterology and hepatology unit, faculty of medicine, Zagazig UniversityAmr ShaabanHanafyInternal Medicine Department, Hepatogastroenterology Unit – Zagazig University. Egypthttps://orcid.org/00MohammedAbdelsattarInternal Medicine Department- Mansura UniversityJournal Article20181103<strong>Background and aim</strong>
There have been significant advancements during the last few years, with large numbers of ongoing trials with various direct-acting antivirals (DAA) showing high potency against the hepatitis C virus (HCV). The aim was to show the effectiveness and side effects of Sofosbuvir-based therapy in treating HCV genotype 4 in Egyptian patients and compare its results with the international results.
<strong>Methods</strong>
The study included 740 patients with chronic HCV. The study population consisted of three groups: Group (1): included 240 patients treated with sofosbuvir 400 mg plus Peginterferon α2a and weight-based ribavirin for 12 weeks. Group (2): had 250 patients treated with sofosbuvir 400 mg and weight-based ribavirin for 24 weeks. Group (3): involved 250 patients treated with sofosbuvir 400 mg and simeprevir 150 mg once daily for 12weeks.
<strong>Results</strong>
Sustained virological response (SVR) occurred in 83.3% of the triple therapy group. In the dual therapy group, SVR occurred in 64% of patients. In the Simeprevir-Sofosbuvir group, SVR was achieved in 96% of patients, with statistically significant differences among the studied groups (p=0.015). Multivariate logistic regression analysis showed that treatment with simeprevir and sofosbuvir was associated with higher rates of SVR with an odds ratio of 12.5. Serum creatinine shows a negative correlation with an odds ratio of 3.1; MELD score showed a negative correlation with an odds ratio of 1.5.
<strong>Conclusion</strong>
Sofosbuvir-based therapy has satisfactory results for the treatment of hepatitis C virus genotype 4 with lesser complicationshttps://ajgh.journals.ekb.eg/article_209236_43c0fd57ca1f0b97ed8f2e52dd4b2674.pdfScientific Society of Kafr El-Sheikh DoctorsAfrican Journal of Gastroenterology and Hepatology2735-54892120190216Difficult To Treat Recurrent Esophageal Dysphagia Due To Secondary Esophageal Motility Disorders: A 24 Weeks Follow Up Case Report1929209246https://dx.doi.org/10.52378/esme881988ENAyman M.E.M.SadekInternal Medicine Department, Hepatogastroenterology Unit – Zagazig Universityhttps://orcid.org/ 0Journal Article20181124Limited data are available on the prevalence of esophageal motility disorders (OMD), with a suggested range of 4-12% in cases with dysphagia. The proposed pathophysiology is either impairment of inhibitory innervation or overactivity of excitatory innervation. The optimal treatment is not defined until now. This case represented one of the secondary OMD in a 70 years year diabetic patient with ischemic cardiomyopathy, who was complaining of recurrent daily intermittent dysphagia to solids and fluids, with a previous vague history of esophageal dilatation without available documentation. After endoscopy with multiple biopsies and barium imaging, the picture of the corkscrew esophagus was revealed. The patient, who was already on nitrates, failed to respond to twice-daily proton pump inhibitor for two months with a prokinetic drug, calcium channel blocker, and the first session of endoscopic esophageal dilatation. After the second dilatation session, we added sodium alginate to substitute nitrates with sildenafil. The patient reported a gradual improvement in dysphagia, especially fluids, decreasing daily attacks. We learned from this case that a different patient-to-patient response necessitates other treatment modalities, even switching between each patient's nitric oxide scavengers.https://ajgh.journals.ekb.eg/article_209246_36c10dd61aa4d9caf3cdfc1fd774a9b0.pdfScientific Society of Kafr El-Sheikh DoctorsAfrican Journal of Gastroenterology and Hepatology2735-54892120190324Targeted drug delivery of capecitabine to mice xenograft gastric cancer by PAMAM dendrimer nanocarrier3055209266https://dx.doi.org/10.52378/fkh195276ENShararehJafariElectrophysiology Research Center, Neurosciences Institute, Tehran University of Medical Sciences, Tehran, IranDepartment of Physiology, Medical school, Tehran University of Medical Sciences, Tehran, IranFatemehNabavizadehDepartment of Physiology, Medical school, Tehran University of Medical Sciences, Tehran, IranJalalVahedianDepartment of Surgery, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, IranMehdi ShafieArdestaniDepartment of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, IranHedayatSamandariElectrophysiology Research Center, Neurosciences Institute, Tehran University of Medical Sciences, Tehran, IranAli ZareMehrjerdiDepartment of Pathology, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, IranJournal Article20190212<strong><em>Aims:</em></strong>
This study used an animal xenograft model of gastric cancer induction to investigate the therapeutic effects of capecitabine polyamidoamine (PAMAM) dendrimer complex against cancer and its potential side effects.
<strong><em>Methods and Materials:</em></strong>
Human gastric cancer tissue was obtained from patients with gastric carcinoma and transplanted into mice. Anticancer drug capecitabine was loaded into PAMAM dendrimer nano-carrier and injected into the animals. All animals received cyclosporine before the surgery.
<strong><em>Results:</em></strong>
Capecitabine-dendrimer complex reduced the size of the axillary implanted tumor, the levels of AST and ALP, and the drug-induced adverse effects on other body organs. Furthermore, it increased apoptotic and necrotic responses in the grafted tumor, RBC, WBC, and platelet counts compared to free capecitabine.
<strong><em>Conclusions:</em></strong>
In gastric cancer settings, the PAMAM dendrimer drug delivery method effectively improved therapeutic index and outcomes and reduced undesirable side-effects of the capecitabine.https://ajgh.journals.ekb.eg/article_209266_2939d6a1fc27a92620d5782d3182f026.pdfScientific Society of Kafr El-Sheikh DoctorsAfrican Journal of Gastroenterology and Hepatology2735-54892120190725Unexpected diagnosis in a patient with liver mass: A case report5664209410http://dx.doi.org/10.52378/asym7783ENMohamed HassanIbrahimInternal Medicine Department, Hepatogastroenterology Unit – Zagazig UniversityJournal Article20190425Sarcoidosis is a rare inflammatory disease. It is characterized by granulomatous formation. The liver is the second most common site for involvement after the lung. Sarcoidosis of the liver is usually asymptomatic. Symptomatic cases can be presented with jaundice, itching, elevated liver enzymes, and the development of portal hypertension in rare situations. We, at the moment, submit a case of liver sarcoidosis in a patient with liver cirrhosis that is presented with upper gastrointestinal bleeding. Upper digestive endoscopy revealed gastric varices. Ultrasonography of the abdomen revealed a suspicious liver mass for hepatocellular carcinoma. There is no cause of gastric varix in this patient apart from hepatic sarcoidosis (portal hypertension). Treatment of patients with corticosteroids leads to the complete disappearance of the liver mass. Despite the high incidence of HCC in Egypt due to the high prevalence of HCV infection, it is crucial to search for the rare causes of hepatic masses.https://ajgh.journals.ekb.eg/article_209410_c63d42f1b31137f6f5eeda1b9927d0d1.pdfScientific Society of Kafr El-Sheikh DoctorsAfrican Journal of Gastroenterology and Hepatology2735-54892120190906Colorectal cancer screening: a mini-review6573209535https://dx.doi.org/10.52378/hsym8873ENMahmoud MohamedZaki5 th grade medical students, faculty of medicine, Zagazig University, Egypt.Mahmoud AbdallahAbdel Said5 th grade medical students, faculty of medicine, Zagazig University, Egypt.Mahmoud Mohamed AliMohamed5 th grade medical students, faculty of medicine, Zagazig University, Egypt.Mahmoud FayezAbdelrasheed5 th grade medical students, faculty of medicine, Zagazig University, Egypt.MahmoudAdel5 th grade medical students, faculty of medicine, Zagazig University, Egypt.Mahmoud MohamedFarag5 th grade medical students, faculty of medicine, Zagazig University, Egypt.Mahmoud MohamedAli5 th grade medical students, faculty of medicine, Zagazig University, Egypt.MahmoudEladly5 th grade medical students, faculty of medicine, Zagazig University, Egypt.MahmoudAbdelwahab5 th grade medical students, faculty of medicine, Zagazig University, Egypt.Journal Article20190707<strong>Background:</strong> Colorectal cancer is increasing worldwide, especially in young populations. <strong>Objective: </strong>In this mini-review, we discussed the different screening methods for colorectal cancer in the general population. <strong>Conclusions:</strong> screening colorectal cancer by other methods is an effective way to diagnose colorectal cancer early.https://ajgh.journals.ekb.eg/article_209535_678e5a9af5b4a4540d4487da7314b70c.pdf